TD Asset Management
ABOS icon

TD Asset Management’s Acumen Pharmaceuticals ABOS Stock Holding History

TD Asset Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-139,206
Closed -$345K – 1247
2024
Q3 		$345K Sell
139,206
-9,594
-6% -$26K ﹤0.01% 1333
2024
Q2 		$360K Hold
148,800
– – ﹤0.01% 1311
2024
Q1 		$603K Buy
+148,800
New +$561K ﹤0.01% 1266

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

TD Asset Management's ABOS Position: Q4 2024 in Review

TD Asset Management sold out of Acumen Pharmaceuticals (ABOS) in Q4 2024, closing a stake of 139,206 shares — an estimated $345K sold.

TD Asset Management first reported a position in ABOS in Q1 2024 and held it in 3 quarters. The position peaked at $603K in Q1 2024. 80 funds tracked by Wall St. Rank hold ABOS as of Q4 2024.

  • TD Asset Management reported no remaining Acumen Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • TD Asset Management sold 139,206 Acumen Pharmaceuticals shares in Q4 2024, an estimated $345K.
  • TD Asset Management first reported a position in Acumen Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • TD Asset Management's Acumen Pharmaceuticals position peaked at $603K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2024.

Based on TD Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.